ResMed

Methodology

ResMed's sleep apnea and respiratory care devices generate predictable recurring revenue from mask replacements and cloud-connected device ecosystems. Aging demographics and sleep apnea awareness drive visibility. The calculation works well for this medical device company with clear replacement cycles and expanding addressable markets in respiratory care.

Methodology

ResMed consistently commands premium PEG ratios reflecting sleep apnea market growth, recurring revenue characteristics, and digital health platform development. While expensive versus traditional med-tech, the defensive growth profile justifies valuations. Compare to ResMed's historical range and respiratory care peers while considering GLP-1 impact debates on sleep apnea prevalence.

Methodology

ResMed offers a modest but growing dividend as management balances capital returns with R&D investments and strategic acquisitions. The dividend adds some value though capital appreciation from market growth dominates. For ResMed, patient base expansion and software-enabled care models matter more than current yield.